CRC cells release lanosterol into the TME where its uptake by CD8+ T cells inhibits the mevalonate pathway, leading to reduced KRAS prenylation, inhibition of downstream KRAS signaling and ultimately CD8+ T cell inactivation. Here, CD8A is linked to colorectal carcinoma.